News | March 06, 2009

Study Suggests Referring Patients with Abnormal Stress Heart Rate Recovery for SPECT Imaging

Researchers at the Section of Cardiology, Department of Medicine, University of Chicago Hospitals said their findings, published in the March 1 issue of the American Journal of Cardiology, Vol. 103, Issue 5, suggest SPECT perfusion imaging should be conducted on patients who have abnormal heart rate recovery (HRR) on routine exercise treadmill testing.

Abnormal HRR after maximal exercise treadmill testing predicts adverse cardiac outcomes, although whether abnormal HRR on exercise treadmill testing should prompt further diagnostic cardiac testing is unknown. This prompted the research team to determine the prevalence of high-risk stress SPECT myocardial perfusion imaging (MPI) findings in patients with abnormal HRR.

A total of 509 men who had been referred for exercise stress MPI and were without other abnormal exercise treadmill testing findings (ischemic electrocardiographic changes or exercise treadmill testing - induced angina) were included in this study. Abnormal HRR was defined as a decrease in heart rate 12 beats at one minute after maximal exercise.

The study found 11 percent of the patients had abnormal HRR. Patients with abnormal HRR had significantly more mild or greater coronary heart disease, severe coronary heart disease, left ventricular dysfunction, and composite high-risk MPI findings compared with those without abnormal HRR. Researchers found on multivariate logistic regression analysis, abnormal HRR was found to be an independent predictor of mild or greater coronary heart disease with a 95 percent confidence interval, severe coronary heart disease, and composite high-risk MPI findings.

The study concluded abnormal HRR on exercise treadmill testing was associated with a high prevalence of abnormal and high-risk stress MPI findings, even in patients without other exercise treadmill testing findings that traditionally would prompt further testing.

For more information: ww.ajconline.org/issues


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now